RECOMENDAÇÕES FRENTE AO CÂNCER DE COLO DE ÚTERO E DE MAMA: a educação em saúde como estratégia de prevenção para a saúde da mulher

  Introduction: Among women worldwide, cervical and breast cancer are among the most prevalent types of cancer. Both cancers have a direct relationship with women's health and are preventable provided preventive measures are taken regularly. Objective: The general objective is to discuss the importance of awareness and care for women's health in the prevention of cervical and breast cancer. Methodology: This is a descriptive and qualitative bibliographic review with an analysis of scientific literature related to the research object. Analysis and discussion of results: Population awareness and health education are essential measures for preventing cervical and breast cancer. Awareness campaigns can contribute to the dissemination of information and reduce the incidence of these types of cancer. It is essential to be aware of the risk factors related to cervical and breast cancer to detect these diseases in early stages. By knowing the signs and symptoms of these neoplasms, women can seek medical help earlier, increasing the chances of cure and reducing mortality. Conclusion: Prevention plays a crucial role in reducing the incidence of cervical and breast cancer. Regular preventive examinations, vaccination, adoption of healthy lifestyles, and health education are some of the main preventive measures for these types of cancer.Introdução: Entre as mulheres em todo o mundo, o câncer de colo de útero e de mama estão entre os tipos de câncer mais prevalentes. Ambos os cânceres têm uma relação direta com a saúde feminina e são passíveis de prevenção, desde que medidas preventivas sejam tomadas de forma regular. Objetivo: tem como objetivo geral discutir a importância da conscientização e do cuidado com a saúde feminina na prevenção do câncer de colo de útero e de mama. Metodologia: Trata-se de uma revisão bibliográfica de caráter descritivo e abordagem qualitativa, com análise de literaturas científicas que nos remetam ao objeto de pesquisa. Analise e discussão dos resultados: A conscientização da população e a educação em saúde são medidas essenciais para a prevenção do câncer de colo de útero e mama. Campanhas de conscientização podem contribuir para a disseminação de informações e para a redução da incidência desses tipos de câncer. É fundamental estar ciente dos fatores de risco relacionados ao câncer de colo de útero e de mama para detectar essas doenças em estágios iniciais. Ao conhecer os sinais e sintomas dessas neoplasias, as mulheres podem procurar ajuda médica mais cedo, aumentando as chances de cura e reduzindo a mortalidade Conclusão: A prevenção desempenha um papel crucial na diminuição da ocorrência de câncer de colo de útero e mama. A realização regular de exames preventivos, a vacinação, a adoção de hábitos de vida saudáveis e a educação em saúde são algumas das principais medidas preventivas para esses tipos de câncer

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Therapeutic Dancing for Parkinson's Disease

Therapeutic dancing has been advocated as an effective adjunct to conventional physical therapies for people living with Parkinson's disease (PD). This systematic review evaluates studies on the outcomes of different dance genres on mobility and quality of life in PD. We searched databases including CINHAL (1982–2015), Medline (1922–2015), Scopus (1996–2015), Web of Science (2002–2015), Embase (2007–2015), PEDro (1999–2015) and the Cochrane Library (1996–2015). The key words were: Parkinson's disease, Parkinson*, Parkinsonism, dance, dance therapy, dance genres, safety, feasibility, and quality of life. Two independent investigators reviewed the texts. Only randomized controlled trials, quasirandomized controlled trials, and case series studies were included. There was emerging evidence that therapeutic dance can be safe and feasible for people with mild to moderately severe PD, with beneficial effects on walking, freezing of gait, and health related quality of life

História e memórias do banco de leite humano do Instituto de Medicina Integral Prof. Fernando Figueira (1987-2009) em Recife, Pernambuco, Brasil History and memories of the human milk bank of the Instituto de Medicina Integral Prof. Fernando Figueira (1987-2009) in Recife, Pernambuco, Brazil

OBJETIVOS: reconstituir a história do Banco de Leite Humano (BLH) do Instituto de Medicina Integral Professor Fernando Figueira (IMIP), enfocando os idealizadores e a inauguração do serviço. MÉTODOS: estudo descritivo, transversal com enfoque histórico, orientado pela metodologia da história oral. Privilegiou-se a consulta a fontes bi¬bliográficas e a entrevista direta a sete participantes, com roteiro estruturado. A análise das falas desvelou duas categorias: "Criação do banco de leite humano do IMIP: os idealizadores e suas influências"; e "A inauguração". RESULTADOS: o BLH do IMIP foi criado em 1987, com a idealização e o incentivo do Professor Fernando Figueira e da Dra. Vilneide Braga, e para suprir as necessidades da Maternidade e da unidade de terapia intensiva neonatal. Da inauguração, participaram autoridades políticas, autoridades em aleitamento materno, celebridades da mídia e profissionais do hospital. CONCLUSÕES: o entrelaçamento entre história e memória, conduzido pelas trilhas da história oral, foi matriz para a construção da origem e evolução do BLH do IMIP, a partir da fala de sujeitos envolvidos nos fatos. A história do BLH do IMIP é um processo inacabado, vivo, é uma força geradora de transformação, sonhos e esperança, que mantém aceso o ideal de um mundo melhor para as crianças, para as mães e para a sociedade.<br>OBJECTIVES: to recount the history of the Instituto de Medicina Integral Professor Fernando Figueira (IMIP)'s Human Milk Bank (HMB), focusing on its pioneers and the introduction of the service. METHODS: a descriptive transversal study with historical focus based on the methods of oral history. The main materials used were bibliographical sources and direct structured interviews with seven participants. Content analysis revealed two categories: "the Creation of the IMIP's Human Milk Bank: its pioneers and their influences"; and "the Introduction of the Service". RESULTS: the IMIP's HMB, set up in 1987, was the brainchild of Professor Fernando Figueira and Dr. Vilneide Braga and its aim was to meet the needs of the Maternity hospital and its neonatal intensive care unit. The inauguration was attended by politicians, breastfeeding experts, TV celebrities and hospital staff. CONCLUSIONS: the methods of oral history were used to build up a history of the origins and evolution of the IMIP's HMB based on the testimony of the individuals involved. The history of the IMIP's HMB is an ongoing, living process and force that produces change, dreams and hope and keeps alight the ideal of a better world for children, mothers and for society at large

A model for community-driven development of best practices: the Ocean Observatories Initiative Biogeochemical Sensor Data Best Practices and User Guide

The field of oceanography is transitioning from data-poor to data-rich, thanks in part to increased deployment of in-situ platforms and sensors, such as those that instrument the US-funded Ocean Observatories Initiative (OOI). However, generating science-ready data products from these sensors, particularly those making biogeochemical measurements, often requires extensive end-user calibration and validation procedures, which can present a significant barrier. Openly available community-developed and -vetted Best Practices contribute to overcoming such barriers, but collaboratively developing user-friendly Best Practices can be challenging. Here we describe the process undertaken by the NSF-funded OOI Biogeochemical Sensor Data Working Group to develop Best Practices for creating science-ready biogeochemical data products from OOI data, culminating in the publication of the GOOS-endorsed OOI Biogeochemical Sensor Data Best Practices and User Guide. For Best Practices related to ocean observatories, engaging observatory staff is crucial, but having a “user-defined” process ensures the final product addresses user needs. Our process prioritized bringing together a diverse team and creating an inclusive environment where all participants could effectively contribute. Incorporating the perspectives of a wide range of experts and prospective end users through an iterative review process that included “Beta Testers’’ enabled us to produce a final product that combines technical information with a user-friendly structure that illustrates data analysis pipelines via flowcharts and worked examples accompanied by pseudo-code. Our process and its impact on improving the accessibility and utility of the end product provides a roadmap for other groups undertaking similar community-driven activities to develop and disseminate new Ocean Best Practices